|
1
|
Siegel RL, Miller KD and Jemal A: Cancer
statistics, 2015. CA Cancer J Clin. 65:5–29. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Conroy T, Desseigne F, Ychou M, Bouché O,
Guimbaud R, Bécouarn Y, Adenis A, Raoul JL, Gourgou-Bourgade S, de
la Fouchardière C, et al: FOLFIRINOX versus gemcitabine for
metastatic pancreatic cancer. N Engl J Med. 364:1817–1825. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Von Hoff DD, Ervin T, Arena FP, Chiorean
EG, Infante J, Moore M, Seay T, Tjulandin SA, Ma WW, Saleh MN, et
al: Increased survival in pancreatic cancer with nab-paclitaxel
plus gemcitabine. N Engl J Med. 369:1691–1703. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Warshaw AL and Fernández-del Castillo C:
Pancreatic carcinoma. N Engl J Med. 326:455–465. 1992. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Li D, Xie K, Wolff R and Abbruzzese JL:
Pancreatic cancer. Lancet. 363:1049–1057. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Stark GR: How cells respond to interferons
revisited: From early history to current complexity. Cytokine
Growth Factor Rev. 18:419–423. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Darnell JE Jr, Kerr IM and Stark GR:
Jak-STAT pathways and transcriptional activation in response to
IFNs and other extracellular signaling proteins. Science.
264:1415–1421. 1994. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Khodarev NN, Beckett M, Labay E, Darga T,
Roizman B and Weichselbaum RR: STAT1 is overexpressed in tumors
selected for radioresistance and confers protection from radiation
in transduced sensitive cells. Proc Natl Acad Sci USA.
101:1714–1719. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Khodarev NN, Minn AJ, Efimova EV, Darga
TE, Labay E, Beckett M, Mauceri HJ, Roizman B and Weichselbaum RR:
Signal transducer and activator of transcription 1 regulates both
cytotoxic and prosurvival functions in tumor cells. Cancer Res.
67:9214–9220. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Khodarev NN, Roach P, Pitroda SP, Golden
DW, Bhayani M, Shao MY, Darga TE, Beveridge MG, Sood RF, Sutton HG,
et al: STAT1 pathway mediates amplification of metastatic potential
and resistance to therapy. PLoS One. 4:e58212009. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Weichselbaum RR, Ishwaran H, Yoon T,
Nuyten DS, Baker SW, Khodarev N, Su AW, Shaikh AY, Roach P, Kreike
B, et al: An interferon-related gene signature for DNA damage
resistance is a predictive marker for chemotherapy and radiation
for breast cancer. Proc Natl Acad Sci USA. 105:18490–18495. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Pitroda SP, Wakim BT, Sood RF, Beveridge
MG, Beckett MA, MacDermed DM, Weichselbaum RR and Khodarev NN:
STAT1-dependent expression of energy metabolic pathways links
tumour growth and radioresistance to the Warburg effect. BMC Med.
7:682009. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Kharma B, Baba T, Matsumura N, Kang HS,
Hamanishi J, Murakami R, McConechy MM, Leung S, Yamaguchi K, Hosoe
Y, et al: STAT1 drives tumor progression in serous papillary
endometrial cancer. Cancer Res. 74:6519–6530. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Meissl K, Macho-Maschler S, Müller M and
Strobl B: The good and the bad faces of STAT1 in solid tumours.
Cytokine. 89:12–20. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Son YO, Lee KY, Lee JC, Jang HS, Kim JG,
Jeon YM and Jang YS: Selective antiproliferative and apoptotic
effects of flavonoids purified from Rhus verniciflua Stokes
on normal versus transformed hepatic cell lines. Toxicol Lett.
155:115–125. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Jang HS, Kook SH, Son YO, Kim JG, Jeon YM,
Jang YS, Choi KC, Kim J, Han SK, Lee KY, et al: Flavonoids purified
from Rhus verniciflua Stokes actively inhibit cell growth
and induce apoptosis in human osteosarcoma cells. Biochim Biophys
Acta. 1726:309–316. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Lee SH, Nan JX, Zhao YZ, Woo SW, Park EJ,
Kang TH, Seo GS, Kim YC and Sohn DH: The chalcone butein from Rhus
verniciflua shows antifibrogenic activity. Planta Med. 69:990–994.
2003. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Samoszuk M, Tan J and Chorn G: The
chalcone butein from Rhus verniciflua Stokes inhibits
clonogenic growth of human breast cancer cells co-cultured with
fibroblasts. BMC Complement Altern Med. 5:52005. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Lee JC, Lim KT and Jang YS: Identification
of Rhus verniciflua Stokes compounds that exhibit free radical
scavenging and anti-apoptotic properties. Biochim Biophys Acta.
1570:181–191. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Lim KT, Hu C and Kitts DD: Antioxidant
activity of a Rhus verniciflua Stokes ethanol extract. Food Chem
Toxicol. 39:229–237. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Kitts DD and Lim KT: Antitumorigenic and
cytotoxic properties of an ethanol extract derived from Rhus
verniciflua Stokes (RVS). J Toxicol Environ Health A. 64:357–371.
2001. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Lee JC, Kim J and Jang YS: Ethanol-eluted
extract of Rhus verniciflua stokes inhibits cell growth and induces
apoptosis in human lymphoma cells. J Biochem Mol Biol. 36:337–343.
2003.PubMed/NCBI
|
|
23
|
Lim KT, Lee SJ, Heo KS and Lim K: Effects
of glycoprotein isolated from Rhus verniciflua stokes on
TPA-induced apoptosis and production of cytokines in cultured mouse
primary splenocytes. Toxicol Lett. 145:261–271. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Choi W, Jung H, Kim K and Lee S, Yoon S,
Park J, Kim S, Cheon S, Eo W and Lee S: Rhus verniciflua stokes
against advanced cancer: A perspective from the Korean Integrative
Cancer Center. J Biomed Biotechnol. 2012:8742762012. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Lee S, Kim K, Jung H, Lee S, Cheon S, Kim
S, Eo W and Choi W: Efficacy and safety of standardized
allergen-removed Rhus verniciflua Stokes extract in patients with
advanced or metastatic pancreatic cancer: A Korean single-center
experience. Oncology. 81:312–318. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Kim JH, Shin YC and Ko SG: Integrating
traditional medicine into modern inflammatory diseases care:
Multitargeting by Rhus verniciflua Stokes. Mediators Inflamm.
2014:1545612014. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Ryu JC: Toxicity free lacquer solution and
device for producing the same. Korean Patent 10-2016-0101802. Filed
August 10, 2016; issued August 10. 2016.
|
|
28
|
Nyegaard S, Christensen B and Rasmussen
JT: An optimized method for accurate quantification of cell
migration using human small intestine cells. Metab Eng Commun.
3:76–83. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Wang Z, Wang Y, Farhangfar F, Zimmer M and
Zhang Y: Enhanced keratinocyte proliferation and migration in
co-culture with fibroblasts. PLoS One. 7:e409512012. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Teng Y, Ross JL and Cowell JK: The
involvement of JAK-STAT3 in cell motility, invasion, and
metastasis. JAKSTAT. 3:e280862014.PubMed/NCBI
|
|
31
|
Bu LL, Deng WW, Huang CF, Liu B, Zhang WF
and Sun ZJ: Inhibition of STAT3 reduces proliferation and invasion
in salivary gland adenoid cystic carcinoma. Am J Cancer Res.
5:1751–1761. 2015.PubMed/NCBI
|
|
32
|
Barnholt KE, Kota RS, Aung HH and Rutledge
JC: Adenosine blocks IFN-gamma-induced phosphorylation of STAT1 on
serine 727 to reduce macrophage activation. J Immunol.
183:6767–6777. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Kovarik P, Stoiber D, Eyers PA, Menghini
R, Neininger A, Gaestel M, Cohen P and Decker T: Stress-induced
phosphorylation of STAT1 at Ser727 requires p38 mitogen-activated
protein kinase whereas IFN-gamma uses a different signaling
pathway. Proc Natl Acad Sci USA. 96:13956–13961. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Andrianifahanana M, Singh AP, Nemos C,
Ponnusamy MP, Moniaux N, Mehta PP, Varshney GC and Batra SK:
IFN-gamma-induced expression of MUC4 in pancreatic cancer cells is
mediated by STAT-1 upregulation: A novel mechanism for IFN-gamma
response. Oncogene. 26:7251–7261. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Perrais M, Pigny P, Ducourouble MP,
Petitprez D, Porchet N, Aubert JP and Van Seuningen I:
Characterization of human mucin gene MUC4 promoter: Importance of
growth factors and proinflammatory cytokines for its regulation in
pancreatic cancer cells. J Biol Chem. 276:30923–30933. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Xie B, Zhao J, Kitagawa M, Durbin J, Madri
JA, Guan JL and Fu XY: Focal adhesion kinase activates Stat1 in
integrin-mediated cell migration and adhesion. J Biol Chem.
276:19512–19523. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Zhang L and Zou W: Inhibition of integrin
β1 decreases the malignancy of ovarian cancer cells and potentiates
anticancer therapy via the FAK/STAT1 signaling pathway. Mol Med
Rep. 12:7869–7876. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Choi HS, Kim MK, Choi YK, Shin YC, Cho SG
and Ko SG: Rhus verniciflua Stokes (RVS) and butein induce
apoptosis of paclitaxel-resistant SKOV-3/PAX ovarian cancer cells
through inhibition of AKT phosphorylation. BMC Complement Altern
Med. 16:1222016. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Choi HS, Seo HS, Kim SR, Choi YK, Jang BH,
Shin YC and Ko SG: Anti-inflammatory and anti-proliferative effects
of Rhus verniciflua Stokes in RAW264.7 cells. Mol Med Rep.
9:311–315. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Andrianifahanana M, Moniaux N, Schmied BM,
Ringel J, Friess H, Hollingsworth MA, Büchler MW, Aubert JP and
Batra SK: Mucin (MUC) gene expression in human pancreatic
adenocarcinoma and chronic pancreatitis: A potential role of MUC4
as a tumor marker of diagnostic significance. Clin Cancer Res.
7:4033–4040. 2001.PubMed/NCBI
|
|
41
|
Chauhan SC, Singh AP, Ruiz F, Johansson
SL, Jain M, Smith LM, Moniaux N and Batra SK: Aberrant expression
of MUC4 in ovarian carcinoma: Diagnostic significance alone and in
combination with MUC1 and MUC16 (CA125). Mod Pathol. 19:1386–1394.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Chaturvedi P, Singh AP, Moniaux N,
Senapati S, Chakraborty S, Meza JL and Batra SK: MUC4 mucin
potentiates pancreatic tumor cell proliferation, survival, and
invasive properties and interferes with its interaction to
extracellular matrix proteins. Mol Cancer Res. 5:309–320. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Bafna S, Singh AP, Moniaux N, Eudy JD,
Meza JL and Batra SK: MUC4, a multifunctional transmembrane
glycoprotein, induces oncogenic transformation of NIH3T3 mouse
fibroblast cells. Cancer Res. 68:9231–9238. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Rachagani S, Macha MA, Ponnusamy MP,
Haridas D, Kaur S, Jain M and Batra SK: MUC4 potentiates invasion
and metastasis of pancreatic cancer cells through stabilization of
fibroblast growth factor receptor 1. Carcinogenesis. 33:1953–1964.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Hollingsworth MA and Swanson BJ: Mucins in
cancer: Protection and control of the cell surface. Nat Rev Cancer.
4:45–60. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Haridas D, Chakraborty S, Ponnusamy MP,
Lakshmanan I, Rachagani S, Cruz E, Kumar S, Das S, Lele SM,
Anderson JM, et al: Pathobiological implications of MUC16
expression in pancreatic cancer. PLoS One. 6:e268392011. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Heinrich PC, Behrmann I, Haan S, Hermanns
HM, Müller-Newen G and Schaper F: Principles of interleukin
(IL)-6-type cytokine signalling and its regulation. Biochem J.
374:1–20. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Kossow C, Jose D, Jaster R, Wolkenhauer O
and Rateitschak K: Mathematical modelling unravels regulatory
mechanisms of interferon-γ-induced STAT1 serine-phosphorylation and
MUC4 expression in pancreatic cancer cells. IET Syst Biol. 6:73–85.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Shishodia S and Aggarwal BB: Guggulsterone
inhibits NF-kappaB and IkappaBalpha kinase activation, suppresses
expression of anti-apoptotic gene products, and enhances apoptosis.
J Biol Chem. 279:47148–47158. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Bafna S, Kaur S, Momi N and Batra SK:
Pancreatic cancer cells resistance to gemcitabine: The role of MUC4
mucin. Br J Cancer. 101:1155–1161. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Ponnusamy MP, Singh AP, Jain M,
Chakraborty S, Moniaux N and Batra SK: MUC4 activates HER2
signalling and enhances the motility of human ovarian cancer cells.
Br J Cancer. 99:520–526. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Chang YM, Kung HJ and Evans CP:
Nonreceptor tyrosine kinases in prostate cancer. Neoplasia.
9:90–100. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Skrypek N, Duchêne B, Hebbar M, Leteurtre
E, van Seuningen I and Jonckheere N: The MUC4 mucin mediates
gemcitabine resistance of human pancreatic cancer cells via the
concentrative nucleoside transporter family. Oncogene.
32:1714–1723. 2013. View Article : Google Scholar : PubMed/NCBI
|
